Company Overview
Snapshot
Founded in February 2024, Pepticore operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on the development of breakthrough antibacterial and antifungal drugs.
Business overview
Pepticore is a Health Tech & Life Sciences company specializing in the development of innovative antibacterial and antifungal drugs. Its core product, PheLiz, is an antibiotic designed to be effective against a broad spectrum of bacterial and fungal species, including antibiotic-resistant microbial strains, due to its unique structure. The company operates within the pharmaceutical sector, addressing critical needs in microbiology and bioconvergence.
Log in to access full profile ›Company Intelligence Q&A
- What is Pepticore's primary focus?
- Pepticore is focused on the development of breakthrough innovations in anti-bacterial and anti-fungal drugs.
- What is Pepticore's flagship product?
- Pepticore's flagship product is PheLiz, an antibiotic active against a wide range of bacterial and fungal species, including antibiotic-resistant strains.
- When was Pepticore founded?
- Pepticore was founded in February 2024.
- What is the current stage of Pepticore's product development?
- Pepticore's product, PheLiz, is currently in the Clinical Trial stage, indicating it is undergoing testing in humans to assess its safety and efficacy.
- What is Pepticore's relationship with Tarom Innovative Technologies?
- Pepticore is a subsidiary of Tarom Innovative Technologies.